IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Quest PharmaTech Inc.
Information provided by (Responsible Party):
Quest PharmaTech Inc.
ClinicalTrials.gov Identifier:
NCT01616303
First received: May 30, 2012
Last updated: September 18, 2017
Last verified: September 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2018 |
| Estimated Primary Completion Date: | December 2017 (Final data collection date for primary outcome measure) |